EGF and EGFR genetic polymorphisms predict prognosis in locally advanced pharyngolaryngeal squamous cell carcinoma patients receiving postoperative concurrent chemoradiotherapy.

Studies on metastatic colorectal cancer populations showed a trend towards better treatment outcomes in patients carrying the EGF61 G/G genotype, while the predictive value of the EGFR R521K genotype was more controversial. 35 – 38 A similar analysis was reported in two studies of recurrent or metastatic SCCHN patients receiving cetuximab-based systemic therapies. 39 , 40 Patients with the EGFR R521K G/G or EGF61 G/G genotypes had better outcomes in response to cetuximab.

also in 53,322 other papers